PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 18, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG

Amivantamab

Given by IV (vein)

DRUG

Tepotinib

Given by PO

Trial Locations (1)

MD Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER

NCT06083857 - PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter